Annual SG&A
$37.44 M
-$104.00 K-0.28%
31 December 2023
Summary:
Poseida Therapeutics annual selling, general & administrative expenses is currently $37.44 million, with the most recent change of -$104.00 thousand (-0.28%) on 31 December 2023. During the last 3 years, it has risen by +$14.41 million (+62.56%). PSTX annual SG&A is now -0.28% below its all-time high of $37.54 million, reached on 31 December 2022.PSTX Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$10.09 M
-$2.09 M-17.16%
30 September 2024
Summary:
Poseida Therapeutics quarterly selling, general & administrative expenses is currently $10.09 million, with the most recent change of -$2.09 million (-17.16%) on 30 September 2024. Over the past year, it has increased by +$2.00 million (+24.72%). PSTX quarterly SG&A is now -17.16% below its all-time high of $12.18 million, reached on 30 June 2024.PSTX Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$2.49 B
-$60.76 M-2.50%
30 September 2024
Summary:
Poseida Therapeutics TTM selling, general & administrative expenses is currently -$2.49 billion, with the most recent change of -$60.76 million (-2.50%) on 30 September 2024. Over the past year, it has dropped by -$2.53 billion (-6669.05%). PSTX TTM SG&A is now -1537.42% below its all-time high of $40.93 million, reached on 30 September 2024.PSTX TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PSTX Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.3% | +24.7% | -6669.1% |
| 3 y3 years | +62.6% | +11.3% | -7478.2% |
| 5 y5 years | +287.0% | +151.9% | -10000.0% |
PSTX Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -0.3% | +62.6% | -17.2% | +24.7% | -81.1% | at low |
| 5 y | 5 years | -0.3% | +287.0% | -17.2% | +151.9% | -1537.4% | at low |
| alltime | all time | -0.3% | +583.3% | -17.2% | +151.9% | -1537.4% | at low |
Poseida Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $10.09 M(-17.2%) | $40.93 M(+5.1%) |
| June 2024 | - | $12.18 M(+24.3%) | $38.93 M(+9.9%) |
| Mar 2024 | - | $9.80 M(+10.6%) | $35.42 M(-5.4%) |
| Dec 2023 | $37.44 M(-0.3%) | $8.86 M(+9.5%) | $37.43 M(-1.3%) |
| Sept 2023 | - | $8.09 M(-6.7%) | $37.94 M(-3.3%) |
| June 2023 | - | $8.68 M(-26.5%) | $39.24 M(-1.4%) |
| Mar 2023 | - | $11.81 M(+26.0%) | $39.80 M(+6.0%) |
| Dec 2022 | $37.54 M(+4.5%) | $9.37 M(-0.2%) | $37.54 M(-0.6%) |
| Sept 2022 | - | $9.39 M(+1.6%) | $37.78 M(+0.9%) |
| June 2022 | - | $9.24 M(-3.2%) | $37.46 M(+1.0%) |
| Mar 2022 | - | $9.55 M(-0.7%) | $37.09 M(+3.3%) |
| Dec 2021 | $35.91 M | $9.61 M(+6.0%) | $35.91 M(+6.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $9.07 M(+2.2%) | $33.78 M(+8.4%) |
| June 2021 | - | $8.87 M(+6.0%) | $31.17 M(+17.5%) |
| Mar 2021 | - | $8.37 M(+11.9%) | $26.54 M(+15.3%) |
| Dec 2020 | $23.03 M(+24.8%) | $7.48 M(+15.8%) | $23.02 M(+17.7%) |
| Sept 2020 | - | $6.46 M(+52.5%) | $19.56 M(+14.3%) |
| June 2020 | - | $4.24 M(-12.7%) | $17.11 M(+1.1%) |
| Mar 2020 | - | $4.85 M(+21.1%) | $16.91 M(-8.4%) |
| Dec 2019 | $18.46 M(+90.8%) | $4.01 M(+0.0%) | $18.46 M(+27.7%) |
| Sept 2019 | - | $4.01 M(-0.9%) | $14.45 M(+38.4%) |
| June 2019 | - | $4.04 M(-36.8%) | $10.44 M(+63.2%) |
| Mar 2019 | - | $6.40 M | $6.40 M |
| Dec 2018 | $9.67 M(+76.6%) | - | - |
| Dec 2017 | $5.48 M | - | - |
FAQ
- What is Poseida Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Poseida Therapeutics?
- What is Poseida Therapeutics annual SG&A year-on-year change?
- What is Poseida Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Poseida Therapeutics?
- What is Poseida Therapeutics quarterly SG&A year-on-year change?
- What is Poseida Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Poseida Therapeutics?
- What is Poseida Therapeutics TTM SG&A year-on-year change?
What is Poseida Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of PSTX is $37.44 M
What is the all time high annual SG&A for Poseida Therapeutics?
Poseida Therapeutics all-time high annual selling, general & administrative expenses is $37.54 M
What is Poseida Therapeutics annual SG&A year-on-year change?
Over the past year, PSTX annual selling, general & administrative expenses has changed by -$104.00 K (-0.28%)
What is Poseida Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of PSTX is $10.09 M
What is the all time high quarterly SG&A for Poseida Therapeutics?
Poseida Therapeutics all-time high quarterly selling, general & administrative expenses is $12.18 M
What is Poseida Therapeutics quarterly SG&A year-on-year change?
Over the past year, PSTX quarterly selling, general & administrative expenses has changed by +$2.00 M (+24.72%)
What is Poseida Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of PSTX is -$2.49 B
What is the all time high TTM SG&A for Poseida Therapeutics?
Poseida Therapeutics all-time high TTM selling, general & administrative expenses is $40.93 M
What is Poseida Therapeutics TTM SG&A year-on-year change?
Over the past year, PSTX TTM selling, general & administrative expenses has changed by -$2.53 B (-6669.05%)